Navigation Links
Upcoming meeting will explore new technologies for glaucoma clinical drug trials

Rockville, MD The National Eye Institute (NEI) and the Food and Drug Administration (FDA) are sponsoring a symposium to consider new disease-relevant outcome measures appropriate for evaluating glaucoma therapies.

Currently, clinical drug trials for glaucoma therapies rely on standard perimetric criteria i.e., a vision field test as the primary functional outcome measure.

However, new technologies that assess abnormalities and changes in the optic nerve structure and its function offer vision researchers alternative pathways to better diagnose and treat glaucoma.

This symposium will focus on new outcome measures appropriate for evaluation of glaucoma therapies. The aim is to encourage the development of new glaucoma therapies, facilitate their evaluation and ultimately benefit patients.

Attendees will include:

  • Clinical researchers/basic scientists
  • Clinical trialists
  • Pharmaceutical company representatives
  • Legal/advocacy firms
  • Associations
  • Biotech companies

Registrants will be able to submit questions/comments in advance through a link on their registration confirmation notice.

Glaucoma facts

Glaucoma a potentially blinding but treatable group of diseases affects 2.2 million Americans age 40 and older, resulting in direct medical costs of $2.86 billion annually.

  • Glaucoma robs individuals of peripheral and eventually central vision.
  • Glaucoma is a complex group of neurodegenerative diseases that arises from progressive damage to the optic nerve and retinal ganglion cells and their axons.
  • It is one of the four major aging eye diseases, alongside age-related macular degeneration, diabetic retinopathy and cataracts.
  • About 50 percent of sufferers are unaware they have the disease.
  • Glaucoma disproportionately affects minority populations: It is three times more common in African Americans than in whites and is the leading cause of irreversible vision loss in African Americans and Hispanics.
  • There is a large public health burden from glaucoma due to decreased productivity, reduced independence and diminished quality of life.


Contact: Lancey Cowan
Association for Research in Vision and Ophthalmology

Related medicine news :

1. Amscot Financial Contributes to the Juvenile Diabetes Research Foundation, Supporting Upcoming Walk for a Cure
2. Align Technology Executives to Present at Upcoming Financial Conferences
3. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
4. The Advisory Board Company to Present at Upcoming Conferences
5. Coherent Announces Director Slate for Upcoming Annual Meeting
6. Poniard Pharmaceuticals Announces Upcoming Conference Participation
7. LCA-Vision Announces Upcoming Investment Community Events
8. WellPoint Announces Appearance at Upcoming Conference
9. Thought Leaders in Morbid Obesity Treatment Convene at Upcoming Surgical Conference
10. GSI to Present at Upcoming Investor Growth Conferences
11. WebMD to Present at Upcoming Investor Conferences
Post Your Comments:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing an ... to overcome a rare and deadly chromosome abnormality. , After struggling since birth ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International ... promote standards of excellence for the field of eating disorders, announces the opening ... 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
Breaking Medicine Technology: